A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131
Karen A. Gelmon(University of British Columbia), Lesley Seymour(Queen's University), Jennifer A. Shabbits(BC Cancer Agency), C. Cripps(Canadian Partnership Against Cancer), Stephen Chia(BC Cancer Agency), S. Huan, S. Janke(BC Cancer Agency), Doug Stewart(Alberta Health Services), K.N. Chi(BC Cancer Agency), L. McIntosh(AIDS Clinical Trials Group), D. Ayers(BC Cancer Agency), Dennis G. Fry(Abbott Fund), William R. Walsh(Sydney Orthopaedic Research Institute)
Cited by 20
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k